BioSpace News Archive

Nemaura Medical, Inc. issued a presentation outlining potential new applications for monitoring disease progression in Covid-19 patients using Continuous Lactate Monitoring.

The pandemic has highlighted the importance of supporting scientific research in order to allow investigators to find real solutions to deal with public health issues such as COVID-19 or cancer.

RTW Investments, LP, (“RTW”) is pleased to announce Ji Xing Pharmaceuticals (“Ji Xing”), have entered into an exclusive licensing agreement for the development and commercialization of CK-274, a next-generation cardiac myosin inhibitor, in Greater China

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its second quarter 2020 financial results after the market closes on Tuesday August 4, 2020. The company’s Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim and Chief Commercial Officer Brandon Perthuis will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT

The Lupus Research Alliance (LRA) is pleased to announce the first recipients of the inaugural LRA-BMS Accelerator Award*, a collaborative project with sponsoring partner Bristol Myers Squibb. The Award provides a collective total of $3,000,000 to support nine cutting-edge lupus research projects over two years that focus on understanding t

Medicago, a biopharmaceutical company headquartered in Quebec City, began Phase I clinical trials for its plant-derived COVID-19 vaccine candidate yesterday, administering the first doses in healthy human volunteers

Aparna Abburi has been named president of Cigna’s Medicare Advantage business.

Therapy Brands has announced Chris Kalb as the General Manager/ Vice President of Operations for TheraNest, MyClientsPlus and Jituzu.

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest-growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced that

The CorNeat KPro, the first synthetic cornea that bio-integrates with the eye wall, received approval to begin a clinical trial at Beilinson Hospital, Israel.